Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icrucumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Icrucumab - Eli Lilly and Company

Alternative Names: 18F1; IMC-18F1; LY 3012212; Monoclonal-antibody-18F1

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Urogenital cancer

Most Recent Events

  • 30 Jul 2021 Discontinued - Phase-II for Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada and USA (IV) before July 2021 (Eli Lilly and Company pipeline, July 2021)
  • 31 Aug 2018 Icrucumab is still in phase II trials for Breast cancer in Canada
  • 01 Jul 2017 Eli Lilly completes a phase II trial in Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second line therapy or greater) in the USA and Canada (NCT01234402)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top